La moxifloxacine est une molécule antibiotique, de la classe des quinolones.↑ Masse molaire calculée d’après « Atomic weights of the elements 2007 », sur www.chem.qmul.ac.uk.

PropertyValue
dbpedia-owl:abstract
  • La moxifloxacine est une molécule antibiotique, de la classe des quinolones.
  • Vorlage:Infobox Chemikalie/Summenformelsuche vorhandenMoxifloxacin ist ein Antibiotikum aus der Gruppe der vierten Generation der Fluorchinolone (Gyrasehemmer) und unterliegt der ärztlichen Verschreibungspflicht.
  • Moxifloxacina é um antibiótico do grupo das fluoroquinolonas que tem por mecanismo de ação a inibição de enzimas responsáveis pela replicação do DNA bacteriano.É uma quinolona nova em comparação com as demais (ciprofloxacina , levofloxacina) e tem em sua molécula a adição de um grupo "metóxi" na posição R2 do anel comum das quinolonas para aumentar sua eficácia contra bactérias atípicas e anaeróbicas.== Referências ==
  • モキシフロキサシン (Moxifloxacin) は、第IIIa世代キノロン系抗菌薬のひとつ。商品名は「アベロックス錠®」。ドイツの製薬メーカーバイエルが開発し、かつて日本では塩野義製薬が販売していた。2010年7月1日より、バイエル薬品の日本法人が製造販売している。また、富士フイルムファーマが販売元として医薬品添付文書に記載されている。また、アルコンが点眼薬として販売しており、日本では日本法人の日本アルコンが取り扱っている。商品名は「ベガモックス®」。
  • Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial agent developed by Bayer AG (initially called BAY 12-8039). It is marketed worldwide (as the hydrochloride) under the brand names Avelox, Avalox, and Avelon for oral treatment. In most countries, the drug is also available in parenteral form for intravenous infusion. Moxifloxacin is also sold in an ophthalmic solution (eye drops) under the brand names Vigamox, and Moxeza for the treatment of conjunctivitis (pink eye). It's antibacterial spectrum includes enteric Gram-(-) rods (Escherichia coli, Proteus species, Klebsiella species), Haemophilus influenzae, atypical bacteria (Mycoplasma, Chlamydia, Legionella), and Streptococcus pneumoniae, and anaerobic bacteria. It differs from earlier antibacterials of the fluoroquinolone class such as levofloxacin and ciprofloxacin in having greater activity against Gram-(+) bacteria and anaerobes. Because of its potent activity against the common respiratory pathogen Streptococcus pneumoniae, it is considered a "respiratory quinolone."A United States patent application was submitted on 30 June 1989, for Avelox (moxifloxacin hydrochloride). In 1999 Avelox was approved by the U.S. Food and Drug Administration (FDA) for use in the United States.In the United States, moxifloxacin is licensed for the treatment of acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community acquired pneumonia, complicated and uncomplicated skin and skin structure infections, and complicated intra-abdominal infections. In the European Union, it is licensed for acute bacterial exacerbations of chronic bronchitis, non-severe community-acquired pneumonia, and acute bacterial sinusitis. Based on its investigation into reports of rare but severe cases of liver toxicity and skin reactions, the European Medicines Agency recommended in 2008 that the use of the oral (but not the IV) form of moxifloxacin be restricted to infections in which other antibacterial agents cannot be used or have failed. In the US, the marketing approval does not contain these restrictions, though the label contains prominent warnings against skin reactions.Avelox (moxifloxacin) was launched in the United States in 1999 and is currently marketed in more than 80 countries worldwide. In the United States, Avelox is marketed by Bayer's partner Merck.In 2011 the FDA added two boxed warnings for this drug in reference to spontaneous tendon ruptures and the fact that moxifloxacin may cause worsening of myasthenia gravis symptoms, including muscle weakness and life-threatening breathing problems.
  • Моксифлоксацин — противомикробное лекарственное средство из группы фторхинолонов ІV поколения.С 2012 года моксифлоксацин включён в Перечень жизненно необходимых и важнейших лекарственных препаратов.
  • Moksyfloksacyna – chemioterapeutyk z grupy fluorochinolonów, zaburzający replikację DNA bakterii (inhibitor gyrazy DNA oraz topoizomerazy IV).Działa bakteriobójczo na bakterie Gram-dodatnie (szczepy Staphylococcus aureus wrażliwe na metycylinę, Streptococcus spp. – w tym S. pyogenes i oporne na antybiotyki szczepy S. pneumoniae), bakterie Gram-ujemne (m.in. Haemophilus influenzae, Moraxella catarrhalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae), bakterie beztlenowe (m.in. Peptostreptococcus spp., Fusobacterium spp.) oraz bakterie atypowe (m.in. Mycoplasma pneumoniae, Legionella pneumophila, Chlamydia pneumoniae).Moksyfloksacyna szybko i niezależnie od pokarmu wchłania się z przewodu pokarmowego (biodostępność około 91%), osiągając stężenie maksymalne we krwi po 0,5-4 h. Z białkami osocza wiąże się w 40-42%. Przenika do tkanek układu oddechowego, m.in. do zatok, błony śluzowej oskrzeli i makrofagów pęcherzykowych. Jest metabolizowana w wątrobie. T0,5 wynosi około 12 h. Jest wydalana w postaci nie zmienionej oraz w postaci metabolitów zarówno z kałem (61%), jak i z moczem.== Przypisy ==
  • La moxifloxacina è un principio attivo che appartiene alla classe dei chinoloni di quarta generazione, sintetizzato nel 1997 e sotto studi clinici.
  • 목시플록사신(Moxifloxacin)은 4세대 합성 플루오르퀴놀론 항세균제로, 바이엘사(Bayer AG, 초기 명칭은 BAY 12-8039)에서 개발하였다. 이 약은 경구 치료제 '아벨록스(Avelox)', 'Avalox', 'Avelon'의 명칭으로 판매된다. 대부분의 나라에서 정맥 투여를 위한 비경구의 형태로도 보급된다. 목시플록사신은 또한 결막염의 치료를 위해 'Vigamox'의 명칭의 안과용 용액(안약)으로도 판매된다.미국에서 아벨록스는 1989년 6월 30일에 특허가 신청되었으나, FDA는 10년 후인 1999년이 되어서야 중증의 생명에 지장이 있는 세균 감염 치료의 용도로 승인하였다. 목시플록사신은 다른 모든 항생제가 실패했을 경우 마지막 수단으로서 고려하도록 그 용도가 제한되었다.목시플록사신은 여러 가지 다른 약제와 영향을 주고 받는다. 이는 다수의 약초와 자연 보충재의 경우에도 그러하다.아벨록스는 1999년을 시작으로 현재 80여개국에서 판매되고 있으며, 시프로플록사신을 대체하였다.
dbpedia-owl:inchi
  • 1/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1
dbpedia-owl:smiles
  • c1(F)cc2c(c(cn(C3CC3)c2c(OC)c1N1C[C@@H]2[C@H](C1)CCCN2)C(O)=O)=O
dbpedia-owl:thumbnail
dbpedia-owl:wikiPageID
  • 4705769 (xsd:integer)
dbpedia-owl:wikiPageLength
  • 6918 (xsd:integer)
dbpedia-owl:wikiPageOutDegree
  • 12 (xsd:integer)
dbpedia-owl:wikiPageRevisionID
  • 108938520 (xsd:integer)
dbpedia-owl:wikiPageWikiLink
prop-fr:c
  • 21 (xsd:integer)
prop-fr:f
  • 1 (xsd:integer)
prop-fr:h
  • 24 (xsd:integer)
prop-fr:inchi
  • 1 (xsd:integer)
prop-fr:inchikey
  • FABPRXSRWADJSP-MEDUHNTEBH
prop-fr:n
  • 3 (xsd:integer)
prop-fr:nom
  • Moxifloxacine
prop-fr:o
  • 4 (xsd:integer)
prop-fr:smiles
  • c1cc2c=O
prop-fr:stdinchi
  • 1 (xsd:integer)
prop-fr:stdinchikey
  • FABPRXSRWADJSP-MEDUHNTESA-N
prop-fr:tailleimage
  • 330 (xsd:integer)
prop-fr:wikiPageUsesTemplate
dcterms:subject
rdf:type
rdfs:comment
  • La moxifloxacine est une molécule antibiotique, de la classe des quinolones.↑ Masse molaire calculée d’après « Atomic weights of the elements 2007 », sur www.chem.qmul.ac.uk.
  • Vorlage:Infobox Chemikalie/Summenformelsuche vorhandenMoxifloxacin ist ein Antibiotikum aus der Gruppe der vierten Generation der Fluorchinolone (Gyrasehemmer) und unterliegt der ärztlichen Verschreibungspflicht.
  • Moxifloxacina é um antibiótico do grupo das fluoroquinolonas que tem por mecanismo de ação a inibição de enzimas responsáveis pela replicação do DNA bacteriano.É uma quinolona nova em comparação com as demais (ciprofloxacina , levofloxacina) e tem em sua molécula a adição de um grupo "metóxi" na posição R2 do anel comum das quinolonas para aumentar sua eficácia contra bactérias atípicas e anaeróbicas.== Referências ==
  • モキシフロキサシン (Moxifloxacin) は、第IIIa世代キノロン系抗菌薬のひとつ。商品名は「アベロックス錠®」。ドイツの製薬メーカーバイエルが開発し、かつて日本では塩野義製薬が販売していた。2010年7月1日より、バイエル薬品の日本法人が製造販売している。また、富士フイルムファーマが販売元として医薬品添付文書に記載されている。また、アルコンが点眼薬として販売しており、日本では日本法人の日本アルコンが取り扱っている。商品名は「ベガモックス®」。
  • Моксифлоксацин — противомикробное лекарственное средство из группы фторхинолонов ІV поколения.С 2012 года моксифлоксацин включён в Перечень жизненно необходимых и важнейших лекарственных препаратов.
  • La moxifloxacina è un principio attivo che appartiene alla classe dei chinoloni di quarta generazione, sintetizzato nel 1997 e sotto studi clinici.
  • Moksyfloksacyna – chemioterapeutyk z grupy fluorochinolonów, zaburzający replikację DNA bakterii (inhibitor gyrazy DNA oraz topoizomerazy IV).Działa bakteriobójczo na bakterie Gram-dodatnie (szczepy Staphylococcus aureus wrażliwe na metycylinę, Streptococcus spp. – w tym S. pyogenes i oporne na antybiotyki szczepy S. pneumoniae), bakterie Gram-ujemne (m.in. Haemophilus influenzae, Moraxella catarrhalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae), bakterie beztlenowe (m.in.
  • Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial agent developed by Bayer AG (initially called BAY 12-8039). It is marketed worldwide (as the hydrochloride) under the brand names Avelox, Avalox, and Avelon for oral treatment. In most countries, the drug is also available in parenteral form for intravenous infusion. Moxifloxacin is also sold in an ophthalmic solution (eye drops) under the brand names Vigamox, and Moxeza for the treatment of conjunctivitis (pink eye).
  • 목시플록사신(Moxifloxacin)은 4세대 합성 플루오르퀴놀론 항세균제로, 바이엘사(Bayer AG, 초기 명칭은 BAY 12-8039)에서 개발하였다. 이 약은 경구 치료제 '아벨록스(Avelox)', 'Avalox', 'Avelon'의 명칭으로 판매된다. 대부분의 나라에서 정맥 투여를 위한 비경구의 형태로도 보급된다. 목시플록사신은 또한 결막염의 치료를 위해 'Vigamox'의 명칭의 안과용 용액(안약)으로도 판매된다.미국에서 아벨록스는 1989년 6월 30일에 특허가 신청되었으나, FDA는 10년 후인 1999년이 되어서야 중증의 생명에 지장이 있는 세균 감염 치료의 용도로 승인하였다. 목시플록사신은 다른 모든 항생제가 실패했을 경우 마지막 수단으로서 고려하도록 그 용도가 제한되었다.목시플록사신은 여러 가지 다른 약제와 영향을 주고 받는다.
rdfs:label
  • Moxifloxacine
  • Moksyfloksacyna
  • Moxifloxacin
  • Moxifloxacin
  • Moxifloxacina
  • Moxifloxacina
  • Моксифлоксацин
  • モキシフロキサシン
  • 목시플록사신
owl:sameAs
http://www.w3.org/ns/prov#wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
foaf:name
  • Moxifloxacine
is dbpedia-owl:wikiPageRedirects of
is dbpedia-owl:wikiPageWikiLink of
is foaf:primaryTopic of